6,262 Shares in Boston Scientific Co. (NYSE:BSX) Purchased by HWG Holdings LP

HWG Holdings LP acquired a new position in Boston Scientific Co. (NYSE:BSX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 6,262 shares of the medical equipment provider’s stock, valued at approximately $482,000. Boston Scientific makes up approximately 0.2% of HWG Holdings LP’s holdings, making the stock its 29th biggest position.

Other large investors also recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new stake in Boston Scientific in the 4th quarter worth about $8,038,000. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Boston Scientific by 225.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after purchasing an additional 73,219 shares during the period. BDF Gestion bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $3,570,000. Precision Wealth Strategies LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $956,000. Finally, Tlwm bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $927,000. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Morgan Stanley boosted their price target on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 24th. BTIG Research boosted their price target on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, July 25th. Finally, Citigroup lifted their price objective on Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.65.

Boston Scientific Stock Up 0.3 %

Shares of BSX opened at $83.35 on Monday. The stock has a market capitalization of $122.28 billion, a price-to-earnings ratio of 70.04, a price-to-earnings-growth ratio of 2.78 and a beta of 0.79. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $84.89. The business’s 50 day simple moving average is $79.33 and its 200-day simple moving average is $75.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.53 EPS. As a group, equities analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.